Metabolic myopathies

1. High-Yield Summary

Metabolic myopathies represent a diverse group of inborn errors of metabolism characterized by biochemical defects in skeletal muscle energy pathways, specifically glycogen breakdown (glycogenoses), mitochondrial long-chain fatty acid oxidation (lipid storage myopathies), and mitochondrial oxidative phosphorylation (respiratory chain cytopathies). Key clinical benchmarks include:

• Triad of Exertional Decompensation: Presentation ranges from exercise intolerance, dynamic exertional myalgia, and premature muscle fatigue to severe electrically silent muscle contractures and life-threatening rhabdomyolysis with myoglobinuric acute kidney injury (AKI).
• Substrate-Specific Triggers: Glycogenolytic defects (e.g., McArdle disease / GSD V, Tarui disease / GSD VII) are triggered by brief, high-intensity anaerobic bursts (sprinting, heavy lifting) and manifest the pathognomonic “second-wind phenomenon” after 6 to 10 minutes of low-intensity exercise. Fatty acid oxidation defects (e.g., carnitine palmitoyltransferase II [CPT II] deficiency) are provoked by prolonged endurance exercise, extended fasting, cold exposure, or febrile illness.
• The Cardinal Anesthetic Rule: Succinylcholine and volatile halogenated inhalational anesthetics are strictly contraindicated due to the extreme risk of malignant hyperthermia-like crises, massive rhabdomyolysis, and fatal hyperkalemic cardiac arrest. Total intravenous anesthesia (TIVA) with propofol and non-depolarizing neuromuscular blockers reversed by sugammadex is mandatory.
• Diagnostic Gold Standards: Next-generation sequencing (NGS) multi-gene neuromuscular panels represent the first-line diagnostic modality, superseded historically by non-ischemic forearm exercise testing (NIFET), cycle ergometry, and targeted muscle biopsy histochemistry. Ischemic forearm testing is strictly obsolete and contraindicated due to high risk of triggering compartment syndrome.
• Surgical Emergency Interface: Severe rhabdomyolysis frequently precipitates secondary acute compartment syndrome (ACS) of the anterior leg or forearm from massive osmotic fluid shifts, mandating emergent multi-compartment fasciotomy, aggressive crystalloid resuscitation (targeting urine output of 2 to 3 mL/kg/h), and urinary alkalinization.

2. Anatomy and Pathophysiologic Substrates

Skeletal muscle bioenergetics depends on three tightly integrated metabolic pathways that produce adenosine triphosphate (ATP) to drive actomyosin cross-bridge cycling and maintain sarcolemmal ion gradients (Na+/K+-ATPase and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase [SERCA]). Disruptions in any component impair mechanical function and compromise sarcolemmal integrity.

Skeletal Muscle Energy Pathways and Fiber Architecture

• Phosphagen System (Creatine Kinase / Phosphocreatine): Provides immediate ATP buffering during the initial 2 to 5 seconds of maximal isometric or isotonic exertion. Intracellular phosphocreatine (PCr) re-phosphorylates ADP via cytosolic creatine kinase (CK-MM).
• Anaerobic Glycogenolysis and Glycolysis: Dominates during high-intensity, anaerobic exercise lasting 5 to 45 seconds (e.g., sprinting, heavy lifting). Muscle glycogen is mobilized by myophosphorylase (PYGM) into glucose-1-phosphate, converted to glucose-6-phosphate, and processed through phosphofructokinase-1 (PFKM) to generate pyruvate, producing a net yield of 3 ATP molecules per glucosyl unit. Under anaerobic conditions, pyruvate reduces to lactate via lactate dehydrogenase (LDH).
• Mitochondrial Fatty Acid Beta-Oxidation (FAO): Serves as the primary energy substrate at rest and during prolonged, low-to-moderate intensity endurance exertion (>40 to 60 minutes) or prolonged fasting. Long-chain fatty acids (LCFAs) require the carnitine shuttle to cross mitochondrial membranes: carnitine palmitoyltransferase I (CPT I) on the outer mitochondrial membrane converts acyl-CoA to acylcarnitine; carnitine-acylcarnitine translocase (CACT) transports acylcarnitine across the inner membrane; and carnitine palmitoyltransferase II (CPT II) reconverts acylcarnitine back to acyl-CoA in the mitochondrial matrix, initiating beta-oxidation into acetyl-CoA, NADH, and FADH2.
• Mitochondrial Oxidative Phosphorylation (OXPHOS): The terminal common pathway in the mitochondrial matrix and inner mitochondrial membrane, comprising Complexes I through V. Electrons derived from NADH and FADH2 generate a proton electrochemical gradient that drives ATP synthase (Complex V), producing 30 to 32 ATP molecules per oxidized glucose molecule.
• Fiber-Type Predilection: Type I fibers (slow-twitch, oxidative) are densely packed with mitochondria and rely on fatty acid beta-oxidation and OXPHOS; they are primarily affected in mitochondrial myopathies and FAO disorders. Type II fibers (fast-twitch, glycolytic) rely heavily on myophosphorylase and glycolysis; they bear the brunt of injury in glycogen storage diseases.

Muscle Biopsy Corridors, Danger Zones, and Internervous Planes

When diagnostic genetic testing is equivocal or reveals variants of uncertain significance (VUS), an open muscle biopsy is performed. Selection of the operative corridor must strictly adhere to anatomic internervous planes to avoid iatrogenic motor denervation, which introduces neurogenic histopathologic artifacts:

3. Pathogenesis

The core pathogenic mechanism unifying all metabolic myopathies is an acute or chronic mismatch between cellular energy demand and ATP synthesis during muscular workload. Depletion of intramuscular ATP precipitates failure of active calcium reuptake into the sarcoplasmic reticulum, generating non-membrane-depolarizing, electrically silent muscle contractures, sarcolemmal dissolution, and massive release of intracellular contents.

Glycogen Storage Diseases (Disorders of Glycogenolysis and Glycolysis)

• Glycogen Storage Disease Type V (McArdle Disease): Autosomal recessive mutation in the PYGM gene on chromosome 11q13 encoding muscle glycogen phosphorylase (myophosphorylase). Complete absence of myophosphorylase blocks the cleavage of alpha-1,4-glucosidic bonds, preventing glycogen mobilization into glucose-1-phosphate. During initial anaerobic exertion, muscle cells cannot generate substrate for glycolysis. Rapid depletion of ATP impairs SERCA pumps, causing persistent actin-myosin cross-bridging (rigor contracture) and severe rhabdomyolysis.
• Glycogen Storage Disease Type VII (Tarui Disease): Autosomal recessive mutation in the PFKM gene on chromosome 12q13.3 encoding muscle phosphofructokinase-1, the rate-limiting enzyme converting fructose-6-phosphate to fructose-1,6-bisphosphate. Similar to McArdle disease, but compounded by erythrocyte PFK deficiency causing mild compensated hemolytic anemia, hyperuricemia, and a paradoxical “out-of-wind” phenomenon where carbohydrate ingestion worsens exercise tolerance due to insulin-mediated suppression of free fatty acid oxidation.
• Glycogen Storage Disease Type II (Pompe Disease / Acid Maltase Deficiency): Autosomal recessive mutation in the GAA gene on chromosome 17q25.2 encoding lysosomal acid alpha-glucosidase. Impairs the hydrolytic degradation of lysosomal glycogen into glucose. Unlike GSD V and VII, Pompe disease is a lysosomal storage disorder leading to progressive accumulation of membrane-bound glycogen, disruption of the autophagy-lysosome system, myofibrillar disorganization, and irreversible proximal limb-girdle, paraspinal, and diaphragmatic muscle atrophy.

Fatty Acid Oxidation and Carnitine Shuttle Defects

• Carnitine Palmitoyltransferase II (CPT II) Deficiency (Myopathic Form): Autosomal recessive mutation in CPT2 on chromosome 1p32.3 (most commonly the Ser113Leu missense mutation). Impairs the inner mitochondrial conversion of palmitoylcarnitine to free carnitine and palmitoyl-CoA. When hepatic glycogen stores are depleted after prolonged low-intensity exertion, prolonged fasting (>12 hours), cold stress, or viral infection, skeletal muscle cannot access long-chain fatty acids for mitochondrial beta-oxidation, precipitating severe bioenergetic failure and rhabdomyolysis.
• Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) and Mitochondrial Trifunctional Protein (MTP) Deficiencies: Autosomal recessive defects in ACADVL and HADHA/HADHB genes causing failure of the initial intramitochondrial dehydrogenation of 14- to 20-carbon fatty acids, leading to toxic accumulation of long-chain acylcarnitines, arrhythmogenic cardiomyopathy, and exercise-induced myoglobinuria.

Mitochondrial Respiratory Chain Cytopathies

Mitochondrial myopathies result from pathogenic variants in either mitochondrial DNA (mtDNA, maternally inherited) or nuclear DNA (nDNA, Mendelian autosomal recessive, dominant, or X-linked) encoding respiratory chain subunits or assembly proteins. Hallmarks include cellular heteroplasmy, where clinical severity correlates with the tissue-specific percentage of mutant mtDNA, and a metabolic threshold effect where tissues with high aerobic demands (skeletal muscle, myocardium, central nervous system) selectively fail.

Cellular Cascade of Contracture, Sarcolemmal Lysis, and Rhabdomyolysis

• ATP Exhaustion and Sarcoplasmic Calcium Overload: When the rate of ATP hydrolysis exceeds regeneration, intracellular ATP levels fall below 30% of normal. Failure of the ATP-dependent SERCA pump prevents calcium sequestration into the sarcoplasmic reticulum. Elevated cytosolic free Ca2+ maintains continuous actin-myosin binding, producing a sustained, involuntary muscle contracture that is electrically silent on electromyography (EMG).
• Proteolytic and Lipolytic Membrane Degradation: Sustained cytosolic calcium hyperactivates neutral calcium-dependent proteases (calpains) and phospholipase A2. These enzymes digest cytoskeletal anchorage proteins (dystrophin, alpha-actinin) and membrane phospholipids, destroying sarcolemmal integrity.
• Cellular Extravasation and Systemic Toxicity: Massive disruption of the sarcolemma allows uncontrolled influx of extracellular sodium, water, and calcium into myocytes, while releasing intracellular constituents into systemic circulation: creatine kinase (CK-MM), myoglobin, potassium, purine nucleotides (converted into uric acid), and phosphate.
• Myoglobinuric Renal Toxicity: Filtered monomeric myoglobin (molecular weight 17.8 kDa) saturates renal tubular reabsorptive capacity. In acidic urine (pH < 5.6), myoglobin precipitates with Tamm-Horsfall protein to form obstructing intratubular casts. Concurrently, heme iron promotes lipid peroxidation, generation of reactive oxygen species, and intense renal medullary vasoconstriction, culminating in acute tubular necrosis (ATN).

4. Natural History

The natural history of metabolic myopathies spans a spectrum from benign exertional myalgia with normal interictal function to recurrent life-threatening rhabdomyolysis and progressive, disabling limb-girdle or axial myopathy:

• Epidemiology and Diagnostic Delay:
  • McArdle Disease: Estimated prevalence is 1 in 100,000 to 1 in 140,000. Symptoms consistently begin in early childhood (inability to keep pace during physical education, early muscle cramping), yet the average diagnostic delay ranges from 15 to 25 years due to misdiagnosis as growing pains, fibromyalgia, chronic fatigue syndrome, or malingering.
  • CPT II Deficiency: The classic adult myopathic form is the most prevalent inherited disorder of lipid metabolism affecting skeletal muscle, typically manifesting between the second and third decades of life. Males are disproportionately diagnosed (approximately 4:1 male-to-female ratio), likely reflecting greater engagement in exhaustive physical conditioning or military service.
  • Late-Onset Pompe Disease (LOPD): Estimated prevalence is 1 in 40,000 to 1 in 57,000 live births, manifesting insidiously in adolescents and adults with progressive proximal pelvic and paraspinal weakness.
• The Second-Wind Phenomenon (Natural History & Kinetics):
  • Pathognomonic for McArdle disease. During the initial 6 to 10 minutes of constant-load aerobic exertion (e.g., cycling or brisk walking), patients experience rapid-onset muscle tightness, severe fatigue, and compensatory resting tachycardia out of proportion to workload (heart rate 150 to 170 bpm at minimal wattage).
  • If the patient slows down or rests briefly without stopping, a sudden subjective and physiological relief occurs after minute 8 to 10: muscle stiffness resolves, perceived exertion falls, and heart rate spontaneously decreases by 20 to 35 bpm despite maintaining the exact same workload.
  • Physiologic Substrate: Reflects the transition from reliance on blocked intramuscular glycogenolysis to systemic energy delivery. Adrenaline-mediated hepatic glycogenolysis releases glucose into the blood stream (circulating free glucose taken up via GLUT4 transporters), accompanied by peripheral vasodilation and increased mobilization of circulating free fatty acids.
• Long-Term Muscular and Renal Prognosis:
  • Recurrent Rhabdomyolysis and AKI: Up to 50% of patients with McArdle disease and over 80% with CPT II deficiency experience at least one episode of massive rhabdomyolysis with myoglobinuria. Acute kidney injury occurs in 20% to 30% of rhabdomyolysis episodes, with 5% to 8% requiring acute hemodialysis.
  • Late-Onset Fixed Myopathy: While episodic metabolic myopathies are classically non-progressive during young adulthood, approximately 25% to 35% of patients with McArdle disease over 40 years of age develop persistent, fixed proximal muscle wasting and weakness, primarily affecting the shoulder girdle, triceps, and hip flexors.
  • Pompe Disease Progression: Without enzyme replacement therapy, LOPD leads to steady loss of ambulation, severe respiratory insufficiency from diaphragmatic paralysis, sleep-disordered breathing, hypercapnic respiratory arrest, and rigid spine syndrome.

5. Clinical Presentation

History

A rigorous, structured clinical history is the most sensitive diagnostic tool for categorizing the underlying metabolic block:

• Trigger Kinetic Profile: Inquire about the exact duration, intensity, and metabolic state of exercise:
  • Brief, intense, anaerobic bursts (seconds to minutes): Sprinting, carrying heavy objects, climbing steep stairs, isometric lifting -> Glycogen storage diseases (GSD V, GSD VII).
  • Prolonged, submaximal, aerobic endurance (>40 to 60 minutes): Long-distance walking, hiking, prolonged cycling, military ruck marching -> Fatty acid oxidation defects (CPT II, VLCAD).
  • Fasting and Catabolic Triggers: Onset during prolonged fasting, caloric deprivation, cold immersion, intercurrent febrile illness, or surgery -> CPT II or VLCAD deficiency.
  • Substrate-Specific Worsening: Worsening of exercise intolerance following a high-carbohydrate or sugary meal (“out-of-wind”) -> Pathognomonic for Tarui disease (PFKM).
• Symptom Progression: Onset of acute painful cramps that fail to respond to stretching (true contractures), accompanied by progressive swelling and tightness.
• Urine Color Changes: Passage of dark, reddish-brown, “cola-colored”, or “tea-colored” urine appearing several hours to two days after heavy exertion, indicating gross myoglobinuria.
• Systemic and Extramuscular Symptoms: Multi-organ involvement points directly away from pure glycogenoses toward mitochondrial cytopathies: ptosis, diplopia, sensorineural hearing loss, progressive cardiomyopathy, gastrointestinal dysmotility, stroke-like episodes, or diabetes.

Physical Examination & Provocative Testing Benchmarks

Between episodes, the physical examination in patients with episodic metabolic myopathies (McArdle, CPT II) is typically normal. Structured provocative testing and meticulous neuromuscular screening provide high diagnostic accuracy:

• The Strict Prohibition on Ischemic Testing: The historic Ischemic Forearm Test (Morgensen test) utilizing an arterial tourniquet inflated to 200 mmHg is strictly contraindicated. Arterial occlusion during maximal contraction rapidly depletes all remaining ATP, triggering irreversible ischemic contracture, acute sarcolemmal necrosis, median and ulnar nerve injury, and forearm compartment syndrome. Only non-ischemic protocols may be performed.
• True Muscle Contracture vs. Normal Muscle Cramp: A regular muscle cramp (e.g., nocturnal gastrocnemius spasm) is caused by hyperactive motor neuron firing and displays continuous, high-amplitude motor unit action potentials on EMG that resolve immediately with passive tendon stretch. A metabolic contracture is an electrically silent actin-myosin rigor lockup; needle EMG demonstrates electrical silence, and passive stretching does not relieve the deformity, which risks muscle tearing.

6. Imaging and Diagnostic Studies

Modern diagnostic pathways prioritize rapid biochemical screening and non-invasive molecular genetics, reserving histochemical muscle biopsy for ambiguous presentations.

Laboratory Biomarkers and Biochemical Profiling

• Serum Creatine Kinase (CK) Kinetics:
  • Interictal Baselines: In McArdle disease, resting CK is persistently elevated in greater than 90% of patients, typically between 1,000 and 5,000 U/L. In CPT II deficiency, resting interictal CK is completely normal in over 60% of patients, rising only during acute decompensation. In mitochondrial myopathies, resting CK is normal or only mildly elevated (200 to 800 U/L).
  • Exertional Spikes: During acute rhabdomyolysis, serum CK rises within 12 hours, peaks at 48 to 72 hours, and often exceeds 50,000 to 200,000+ U/L. Serum CK > 5,000 U/L defines a high risk of developing acute kidney injury.
• Urinalysis and the “Orthotolidine Discrepancy”:
  • The automated dipstick reagent tests positive for heme (orthotolidine oxidation), which cannot distinguish between red blood cells, hemoglobin, and myoglobin.
  • Pathognomonic Finding: Dipstick reveals “4+ Large Blood” or “Heme Positive,” yet microscopic urinalysis shows 0 to 2 RBCs per high-power field. Centrifugation of urine yields clear supernatant in hematuria, but pigmented reddish-brown supernatant in myoglobinuria. Centrifugation of blood shows clear serum in myoglobinuria (rapidly cleared by kidneys), whereas serum is pink/red in intravascular hemolysis (haptoglobin-binding threshold exceeded).
• Plasma Acylcarnitine Profile (Tandem Mass Spectrometry): First-line diagnostic screen for fatty acid oxidation defects. In CPT II deficiency, tandem MS reveals elevated long-chain acylcarnitines, specifically palmitoylcarnitine (C16) and oleylcarnitine (C18:1), along with a significantly elevated (C16 + C18:1)/C2 ratio. In VLCAD deficiency, tetradecenoylcarnitine (C14:1) is elevated.
• Serum Lactate and Pyruvate Dynamics: Resting venous lactate > 2.5 mmol/L and an elevated lactate-to-pyruvate ratio (> 20:1) suggest mitochondrial respiratory chain defects. Normal resting lactate does not exclude mitochondrial myopathy; an abnormal lactate elevation during light cycling is highly sensitive.
• Dried Blood Spot (DBS) Acid Alpha-Glucosidase Assay: Mandatory first-line screening test for suspected late-onset Pompe disease. Marked reduction in GAA enzyme activity on DBS is subsequently confirmed via leukocyte or fibroblast enzymatic fluorometry and GAA sequencing.

Next-Generation Sequencing (NGS) Gene Panels

Targeted comprehensive multi-gene NGS panels encompassing 50 to 150 neuromuscular and metabolic genes have become the preferred first-line diagnostic standard, avoiding invasive muscle biopsies in >85% of cases. Panels must include PYGM (McArdle), PFKM (Tarui), GAA (Pompe), CPT2, ACADVL (VLCAD), HADHA/HADHB (MTP), ETFA/ETFB/ETFDH (MADD), LPIN1 (lipin-1), and nuclear-encoded mitochondrial genes (e.g., POLG, TWNK), supplemented by full mitochondrial genome sequencing.

Muscle Biopsy Histochemistry and Electron Microscopy

Muscle biopsy is reserved for cases with ambiguous genetic findings, novel variants, or high clinical suspicion with negative targeted panels:

Magnetic Resonance Imaging (Muscle MRI)

• T1-Weighted Fast Spin Echo (Anatomic & Fatty Infiltration): Detects selective patterns of chronic fatty replacement. In late-onset Pompe disease, T1-weighted images show characteristic selective wasting and fatty degeneration of the adductor magnus, semimembranosus, gluteus maximus, and paraspinal musculature, with relative sparing of the rectus femoris and gracilis.
• Short Tau Inversion Recovery (STIR) / T2-Dixon: Highly sensitive for identifying active, subacute muscle edema, inflammation, and ongoing rhabdomyolysis. STIR identifies affected muscle compartments to guide fasciotomy decisions and optimal biopsy sites (avoiding end-stage fatty fibro-adipose tissue which yields non-diagnostic samples).

7. Classification

Metabolic myopathies are classified based on the biochemical pathway affected, specific genetic etiology, trigger kinetics, and associated surgical or life-threatening risks:

8. Treatment

Medical / Nonoperative Management

First-line management centers on pathway-specific nutritional modulation, proactive substrate administration, avoidance of catabolic fasting, and aerobic exercise conditioning:

• Substrate-Specific Nutritional Therapy:
  • McArdle Disease (GSD V): Ingestion of simple carbohydrates (37 to 40 g of oral sucrose, e.g., commercial sports beverage or sucrose in water) consumed precisely 30 to 40 minutes prior to planned physical exertion. Circulating systemic glucose bypasses the blocked myophosphorylase pathway via GLUT4 uptake, significantly lowering heart rate, improving workload capacity, and preventing contractures. A high-protein diet (2.0 to 2.5 g/kg/day) provides amino acid substrates for hepatic gluconeogenesis.
  • Tarui Disease (GSD VII): Carbohydrate ingestion prior to exercise is strictly contraindicated. Supplying oral glucose causes an insulin spike that suppresses adipose lipolysis and hepatic ketone generation, starving the muscle of alternative oxidative fuels and precipitating the “out-of-wind” phenomenon. Patients must rely on a protein- and lipid-balanced diet.
  • CPT II and Long-Chain FAO Deficiencies: Low-fat (<20% of total calories), high-carbohydrate diet, with frequent meals to avoid fasting exceeding 8 to 10 hours. Supplementation with Medium-Chain Triglyceride (MCT) oil (1 to 2 g/kg/day) or odd-chain triglyceride (triheptanoin) directly enters the mitochondrial matrix independently of the CPT I/II carnitine shuttle, providing acetyl-CoA and anaplerotic propionyl-CoA for the citric acid cycle.
  • Late-Onset Pompe Disease: Recombinant human acid alpha-glucosidase (rhGAA; alglucosidase alfa or avalglucosidase alfa) enzyme replacement therapy (ERT) administered intravenously every two weeks slows pulmonary decline, stabilizes vital capacity, and prolongs independent ambulation.
• Aerobic Conditioning Protocols: Patients should engage in supervised, moderate-intensity aerobic exercise (e.g., stationary cycling, brisk walking, swimming) for 30 to 40 minutes, 3 to 5 times weekly. Regular aerobic conditioning upregulates mitochondrial biogenesis, expands capillary density, increases free fatty acid transport, and facilitates early transition into the second wind. High-resistance isometric training and eccentric loading are strictly contraindicated.
• Emergency Medical Management of Acute Rhabdomyolysis:
  • Aggressive Fluid Resuscitation: Immediate intravenous administration of isotonic crystalloids (normal saline or lactated Ringer’s) at 200 to 300 mL/h, titrating to maintain a target urine output of 2 to 3 mL/kg/h (or 200 to 300 mL/h in adults).
  • Urinary Alkalinization: Infusion of sodium bicarbonate (100 to 150 mEq/L in 5% dextrose) targeting a urinary pH > 6.5. Alkalinization prevents myoglobin precipitation into Tamm-Horsfall casts and mitigates renal tubular lipid peroxidation, provided hypocalcemia and severe metabolic alkalosis are closely monitored.
  • Electrolyte Correction: Hyperkalemia represents the primary cause of immediate death in rhabdomyolysis; treat emergently with intravenous calcium gluconate (stabilizes myocardium), insulin with dextrose, nebulized albuterol, and potassium binders. Loop diuretics (furosemide) are reserved for volume overload; mannitol is no longer routinely recommended due to risk of hyperosmolality and nephrotoxicity.

Operative Management

Surgical intervention in patients with metabolic myopathies is indicated for definitive diagnostic tissue harvest, emergency decompression of rhabdomyolysis-induced compartment syndrome, or correction of secondary musculoskeletal deformities:

• Diagnostic Muscle Biopsy Technique:
  • Anesthetic Protocol: Infiltrate 1% lidocaine strictly into the skin and subcutaneous fat. Never inject local anesthetic directly into the muscle belly; local anesthetics cause depolarization artifact, myofibrillar vacuolation, and false-positive histologic necrosis.
  • Specimen Handling: Expose the muscle fascia through a 3 cm longitudinal incision. Place two parallel stay sutures 1.5 cm apart along the longitudinal orientation of the muscle fibers. Apply a dedicated isometric muscle biopsy clamp to maintain resting sarcomere length before sharply excising a 1.5 x 0.5 x 0.5 cm cylinder. Avoid electrocautery near the specimen to prevent thermal coagulative artifact.
  • Laboratory Dispatch: Segment the biopsy into three portions: (1) snap-freeze in isopentane cooled in liquid nitrogen for histochemistry/enzymology; (2) fix in buffered 2.5% glutaraldehyde for electron microscopy; (3) wrap in saline-dampened gauze on wet ice for immediate mitochondrial biochemical respiratory chain assays.
• Emergency Fasciotomy for Acute Compartment Syndrome (ACS):
  • Rhabdomyolysis triggers massive intracellular osmotic fluid shifts, expanding muscular volume and elevating intracompartmental pressures within non-compliant osteofascial envelopes. When delta pressure (diastolic blood pressure minus intracompartmental pressure) drops to <= 30 mmHg, emergency multi-compartment fasciotomy is mandatory.
  • Lower Leg (Two-Incision Four-Compartment Decompression): Anterolateral incision releases anterior and lateral compartments; posteromedial incision releases superficial and deep posterior compartments. The deep posterior compartment release must detach the soleus bridge from the tibial margin.
  • Forearm Decompression: Extensive volar curvilinear Bruner or flexor incision releasing the superficial and deep flexor compartments, extending across the carpal tunnel, paired with a dorsal longitudinal incision to decompress mobile wad and dorsal extensor compartments.
  • Serial Debridement Strategy: Intraoperatively, inspect muscle for viability (4 Cs: color, consistency, contractility, capacity to bleed). In metabolic rhabdomyolysis, muscle that appears pale and non-contractile may recover once compartment pressure is released; avoid aggressive primary excision of viable-appearing pale muscle. Perform generous fasciotomies, apply negative pressure wound therapy (NPWT), and return for a planned second-look debridement at 48 hours.
• Orthopaedic Reconstructive Surgery:
  • Patients with late-onset Pompe disease frequently develop rigid spine syndrome, severe progressive scoliosis, and heel-cord contractures. Corrective spinal fusion or tendon lengthenings (Achilles tendon lengthening, hamstring release) require comprehensive preoperative pulmonary evaluation (forced vital capacity in both sitting and supine positions) and proactive non-invasive ventilation planning.

Indications & Contraindications

9. Outcome

Long-term functional preservation and survival depend on timely diagnostic identification, rigorous adherence to substrate-specific dietary regimens, and aggressive prevention of acute renal failure:

• Functional Preservation and Exercise Capacity:
  • McArdle Disease: Implementation of pre-exercise oral sucrose protocols paired with regular, low-intensity aerobic conditioning increases peak oxygen uptake (VO2 peak) by 20% to 25% and reduces the annual incidence of severe rhabdomyolysis by over 75%. Longitudinal registry cohorts demonstrate that patients who maintain aerobic fitness preserve independent functional mobility and score comparably to healthy controls on validated physical outcome measures (SF-36 physical functioning component).
  • CPT II Deficiency: Dietary management featuring frequent high-carbohydrate meals and avoidance of fasting reduce recurrent rhabdomyolytic events to less than 0.1 episodes per patient-year. Long-term muscular strength remains preserved without premature muscle wasting.
  • Late-Onset Pompe Disease: Recombinant enzyme replacement therapy produces significant, durable clinical benefits. Landmark clinical trials confirm stabilization of pulmonary function (forced vital capacity) and a mean improvement of 25 to 35 meters in the 6-minute walk test (6MWT) maintained over 3 to 5 years, arresting the historical trajectory toward wheelchair dependence.
• Renal Outcomes and Survivorship:
  • With early, protocolized crystalloid resuscitation initiated within 6 hours of rhabdomyolysis onset, overall mortality is less than 2%, and the requirement for acute renal replacement therapy (hemodialysis) remains under 8%.
  • In patients who develop oliguric acute tubular necrosis requiring temporary hemodialysis, over 90% achieve full recovery of baseline renal filtration (eGFR) within 3 to 6 months, provided secondary interstitial fibrosis is minimized.

10. Complications

Complications of metabolic myopathies are categorized chronologically and by pathophysiologic phase:

11. Pearls and Pitfalls

• The Second-Wind Differentiation Pearl: When taking the history of an athlete presenting with exertional myalgia, always ask: “If you develop muscle stiffness while jogging, does it ease if you slow down and keep moving for 10 minutes?” A positive answer establishes McArdle disease (GSD V). In contrast, patients with CPT II deficiency or mitochondrial myopathies experience worsening pain that never eases until complete cessation of exercise.
• Pre-Exercise Sucrose Timing: In McArdle disease, oral sucrose (37 to 40 g) must be consumed exactly 30 to 40 minutes prior to exercise. Ingesting sugar too early (e.g., 90 minutes prior) triggers an insulin spike that drives blood glucose into adipose tissue, leaving the patient hypoglycemic and metabolically starved right as exercise begins.
• Urine Dipstick vs. Microscopic Urinalysis Discrepancy: A urine dipstick reading “4+ Large Blood” in a clear centrifuged supernatant with 0 to 2 red blood cells per high-power field under microscopy is pathognomonic for myoglobinuria. Never assume gross hematuria or renal trauma without examining the sediment.
• Pitfall – The Ischemic Forearm Test: Never perform an ischemic forearm exercise test using an inflated arterial cuff. In patients with glycogenoses, ischemic contraction rapidly depletes residual ATP, provoking irreversible rigor contracture, muscle necrosis, and acute forearm compartment syndrome. Always utilize non-ischemic protocols.
• Pitfall – Aggressive Fasciotomy Debridement: During emergent fasciotomy for rhabdomyolytic compartment syndrome, muscle bellies often appear pale, edematous, and non-contractile. Do not aggressively excise this muscle at index decompression; tissue viability frequently recovers once intracompartmental hypertension is relieved. Perform wide fascial releases, apply NPWT, and reassess viability at a planned 48-hour second look.
• Pitfall – Preoperative Fasting Catabolism: Never subject a patient with suspected or confirmed CPT II deficiency to prolonged preoperative fasting. Fasting beyond 8 hours depletes glycogen and shifts metabolism toward blocked long-chain fatty acid oxidation, precipitating acute perioperative rhabdomyolysis. Maintain continuous intravenous 10% dextrose infusion throughout the perioperative window.

12. Controversy

Three primary controversies prompt ongoing debate in the management of metabolic myopathies:

• Ketogenic Diets in Glycogen Storage Diseases: A ketogenic diet (very high-fat, very low-carbohydrate) has been hypothesized to bypass blocked muscle glycogenolysis by elevating circulating beta-hydroxybutyrate and acetoacetate to serve as alternative mitochondrial fuels. While small cohort studies have reported modest improvements in exercise tolerance in select patients with McArdle disease, other trials report worsened fatigue, hyperlipidemia, and accelerated hepatic glycogen loading. Consensus guidelines currently recommend a balanced, complex-carbohydrate diet with pre-exercise simple carbohydrates for GSD V, reserving ketogenic protocols as experimental.
• Gene Therapy Vectors vs. Recombinant Enzyme Delivery: Recombinant adeno-associated virus (rAAV) vector-mediated gene delivery aiming for definitive gene replacement (e.g., delivering PYGM or GAA) is currently in preclinical and early-phase clinical trials. Significant technical hurdles include achieving therapeutic vector biodistribution across the entire skeletal muscle mass (which accounts for ~40% of total body weight), preventing neutralizing anti-AAV immune responses, and mitigating high-dose systemic hepatotoxicity. In Pompe disease, the comparative efficacy of next-generation enzyme replacement therapies (with enhanced cellular uptake via bis-mannose-6-phosphate tagging) versus systemic gene therapy remains an active area of investigation.
• Routine Allopurinol Prophylaxis for Myogenic Hyperuricemia: Rapid degradation of muscular adenine nucleotides (ATP -> ADP -> AMP -> inosine -> hypoxanthine -> uric acid) during energy crisis results in post-exertional hyperuricemia, predisposing patients to secondary gout and urate nephropathy. Whether all patients with GSD V and GSD VII should receive continuous xanthine oxidase inhibitor therapy (allopurinol or febuxostat) versus on-demand hydration and urine alkalinization during symptomatic rhabdomyolysis remains controversial.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Quinlivan R, Martinuzzi A, Schoser B. Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V). Cochrane Database Syst Rev. 2014. doi:10.1002/14651858.CD003458.pub5 [Level I: Cochrane Systematic Review & Meta-Analysis]
• Lucia A, Martinuzzi A, Nogales-Gadea G et al. Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group. Neuromuscul Disord. 2021. doi:10.1016/j.nmd.2021.10.006 [Level IV: International Consensus & Practice Guidelines]
• Tarnopolsky MA. Metabolic Myopathies. Continuum (Minneap Minn). 2022. doi:10.1212/CON.0000000000001182 [Level IV: Clinical State-of-the-Art Review]
• Ørngreen MC, Olsen DB, Vissing J. Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose. Neurology. 2002. doi:10.1212/wnl.59.7.1046 [Level I: Randomized Controlled Crossover Trial]
• Stahl K, Rastelli E, Schoser B. A systematic review on the definition of rhabdomyolysis. J Neurol. 2020. doi:10.1007/s00415-019-09185-4 [Level I: Systematic Review & Diagnostic Synthesis]

15. Master Class Pro-Tip

When an orthopaedic patient with known or suspected metabolic myopathy presents for surgery, standard anesthetic protocols must be immediately suspended. Depolarizing muscle relaxants (succinylcholine) and all volatile halogenated inhalational anesthetics are absolutely contraindicated due to the lethal risks of hyperkalemic cardiac arrest and rhabdomyolytic hyperthermia-like reactions. Mandate Total Intravenous Anesthesia (TIVA) utilizing propofol, short-acting opioids, and non-depolarizing agents (rocuronium) with immediate sugammadex reversal availability. To prevent perioperative catabolic crisis—especially in fatty acid oxidation defects—preoperative fasting must never exceed 6 hours without initiating continuous intravenous 10% dextrose infusion. Intraoperatively, avoid prolonged pneumatic tourniquet ischemia, as distal limb hypoxemia directly precipitates local sarcolemmal energy depletion and post-deflation rhabdomyolysis. Postoperatively, maintain aggressive isotonic crystalloid hydration targeting a urine output of 2 to 3 mL/kg/h, track serum CK and potassium every 6 hours for 48 hours, and maintain a low threshold for emergent multi-compartment fasciotomy if tense swelling or pain out of proportion develops.

Master Class Surgical Pearl: Perioperative & Anesthetic Precautions in Metabolic Myopathies